Vista Pharma posts nil revenue with going concern flag

Going ConcernPat NegativeRevenue DeclineResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-8.6%Reaction day

₹6.89

prior close

₹6.35

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-8.7% vs market

Pharmaceuticals peers, median of 167sector-0.3%-8.2% vs sector

On the reaction day the stock moved 8.7 pts less than Nifty Microcap 250 and 8.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+9.9

10m

+9.9

15m

+9.9

30m

+5.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-8.6+0.1-8.7-0.3-8.2

Next day

-8.9+0.5-9.4-0.0-8.8

-4.8-0.1-4.7-0.7-4.1

-8.6+0.4-9.0-0.4-8.2

-6.5+0.7-7.2-0.7-5.9

-4.1+0.9-5.0-0.5-3.5

-14.9+1.1-16.1-0.7-14.2

15d

-9.9+1.6-11.5+1.4-11.2

-15.2-0.7-14.5+0.6-15.8

-11.5-3.2-8.2-4.1-7.3

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vista Pharmaceuticals reported zero revenue from operations in Q1 FY27 versus Rs 151.88 lakhs a year ago. Net loss narrowed to Rs 98.59 lakhs from Rs 129.04 lakhs. Company flagged material uncertainty about going concern due to NPA classification of credit facilities, defaults on bank borrowings, and negative working capital with current liabilities exceeding assets by Rs 183.32 lakhs. Management cited debt restructuring and share warrant call money of Rs 922.49 lakhs.

Likely market impact

Severe going concern risk with NPA status, nil revenue and six straight years of losses. High-risk for shareholders.